Building our Multidisciplinary Membership

ANZUP Operational Report Continued

NHMRC Clinical Trials Centre

ANZUP collaborates with the National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC) to conduct clinical trials to improve urogenital and prostate cancer treatment and patient outcomes .

In February 2013 we said goodbye to Trevor France who had overseen clinical trial management for ANZUP over 12 months . We were delighted to welcome our new AOPM Xanthi Coskinas . Xanthi has been employed at the CTC for the past 10 years . In 2007 she was appointed AOPM for the ALTG collaborative group and now her role has broadened to include oversight of CTC clinical trial operations for ANZUP whilst maintaining her current position on ALTG . Our thanks to Jennifer Thompson and Angus McDonald for their ongoing efforts to support ANZUP trial activities . In the beginning of the year we also welcomed Dr Anne Long, ANZUP’s new Research Fellow . Anne is a medical oncologist from Perth who is currently working as our ANZUP Clinical Trials fellow at the NHMRC Clinical Trials Centre at the University of Sydney . She has previously completed an honours degree in Psychology and is currently working on obtaining her Masters in Clinical Trials Research . She has an interest in bladder and renal cancers and is enjoying the challenge of working in clinical trials .

We are grateful to Martin Stockler, co-director of Oncology at CTC and our SAC Deputy Chair for his ongoing support and commitment to ANZUP . To the operational staff at CTC Kim Russell Cooper, General Manager, Lia Sherwood, Paul Smyth, Finance Manager, Carlos Sterling, Dinh Tran and his IS team our thanks for your support and cooperation in matters relating to ANZUP and the CTC .

Xanthi Coskinas Dr Anne Long

Building our multidisciplinary membership:

As at 31 March 2013, ANZUP had 530 members covering a wide range of professional disciplines . The breakdown of membership was as follows:

Number of members by State/Territory in Australia:

Trainee 31

Anaesthetist 1

Physiologist 1 Radiologist 2 Pharmacist 3

Nuclear Medicine 2 Consumer 21

Scientist 30

Endocrinologist 3 Health Economics 3

Allied Health 12

General Practice 1 Pathologists 8 Clinical Epidemiology 6 Psycho-oncology & Supportive care 26 Nursing 49 Radiation Oncologying 45 Urologic Surgery 98 Medical Oncology 120

In the past year ANZUP membership has grown 31%

WA:39 NT:5

SA:25 QLD:60

NSW:210

VIC:147 ACT:14

TAS:5

Rest of the world; Canada: 4 United States: 2 United Kingdom: 1 New Zealand: 18

In summary

ANZUP mission is to conduct high quality investigator initiated clinical trials to improve the treatment for those affected by prostate, bladder, kidney and testicular cancers . It is only through the ongoing commitment of our hard working Board and members, staff and volunteers, donors, Corporate Supporters and our stakeholders that we will continue to achieve our mission and objectives . To all our clinical trial participants thank you for your participation .

ANZUP ASM 2012 Report: Peter Grimison

Our highly successful and first stand-alone Annual Scientific Meeting was held in Sydney on 15-17 July 2012 . Over 190 delegates attended a feature packed program, including the contribution of our four outstanding international speakers: Daniel Heng, Shahrokh Shariat, Michel Bolla and Donna Berry . The interaction amongst attendees was very encouraging, and we hope will lead to several future research collaborations and ANZUP trials .

Pre-conference Meetings: Kicking off on the Sunday was our Trainee Day coordinated by Shomik Sengupta and Paul Sved . Many thanks to the chairs, panellists and of course the attendees . The day saw a series of case based discussions that covered the major urological cancers . They included aspects of medical management and supportive care across disciplines; as well as clinical, psychosocial and translational research . This was a very successful day with very positive feedback and we are planning to continue our trainee days pre our ASM . Sunday also saw an educational forum for the ANZUP Consumer Advisory Panel, followed by the ANZUP Community Engagement Forum entitled, “A little below the belt .” This forum showcased both consumers and clinical leaders and was intended to improve awareness of clinical trials and to facilitate community involvement .

The forum was followed by an open meeting of the ANZUP Scientific Advisory Committee which was extremely well attended and saw lots of good discussion .

The conference was officially opened by the Federal Minister for Health, the Honourable Tanya Plibersek, who acknowledged the importance of cooperative trials groups in progressing cancer research in Australia .

ASM Report Continued

The first plenary session of the day was a highlight with presentations from our international and local experts . Dr Shariat discussed the importance of multi-disciplinary cooperation in the optimal treatment of bladder cancer, which was a theme carried through in several other presentations during the meeting . Our own A/Prof Guy Toner, covered the changing management paradigm in the treatment of Stage I testicular cancer . Dr Donna Berry (Harvard) presented research into a unique decision support tool for prostate cancer patients, emphasising the importance of individualised patient information and Prof Michel Bolla discussed the ongoing controversies in the role of postprostatectomy radiotherapy, some of which may be answered by the ongoing Australian RAVES study .

The theme for the Monday afternoon session was minimising the adverse effects of treatment . Adverse effects of prostate cancer therapy may significantly affect men’s quality of life . Dr Chris McMahon discussed sexual rehabilitation for these patients, and A/Prof Jim Denham presented preliminary results on toxicity and quality of life in men treated with androgen deprivation therapy on the TROG RADAR study . Treating patients with co-morbidities is frequently challenging, and Dr Daniel Heng discussed the safe use of tyrosine kinase inhibitors in patients with organ failure . Tuesday kicked off with a breakfast session focussing on the optimal use of androgen deprivation therapy in prostate cancer, with presentations from Dr Donna Berry and Prof Michel Bolla . The Australian research showcase was a highlight of the day, with thought provoking presentations from some of our best researchers from around the country . The session concluded with a very moving presentation from Belinda Jago, one of our new ANZUP CAP members, who gave us some insight into her experience of being involved in clinical trials, as a carer and mother for her daughter Bec, who was diagnosed with metastatic renal cell carcinoma at the age of 15 and died at 19 .

Tuesday afternoon was focussed on new frontiers of prostate cancer treatment . A/Prof Howard Gurney gave an overview of the exciting developments in the systemic treatment of castrate-resistant prostate cancer, and Dr Ron Shnier covered the other end of the disease spectrum – the role of prostate MRI in active surveillance of prostate cancer . The afternoon concluded with an entertaining debate between Michel Bolla and Sharokh Shariat on the optimal treatment of prostate cancer, which in the end, demonstrated that there is more agreement than disagreement, and that a patients focussed, multi-disciplinary approach is key .

A highlight of the meeting was the research presentations . Monday afternoon saw a very vigorous concept development session, which demonstrated the value of the ANZUP membership and international faculty in refining study proposals that we hope will be translated into ANZUP studies . There were four disease-specific research sessions which saw updates of ANZUP trials and research collaborations across prostate cancer, renal cell cancer, germ cell tumours, and bladder cancer . The Best of the Best abstracts showcased recent research by outstanding Australian investigators . There was also a very successful poster walk-around session on the Monday evening which gave presenters an opportunity to interact with the attendees and develop future collaborations .

Awards and Social Events

A welcome reception followed the pre-conference meetings on the Sunday, and set the stage for keen conversations between attendees . The Monday concluded with the ANZUP ASM 2012 conference dinner in the Ballroom . It was an evening of great food & wine, ongoing multi-disciplinary collaboration, with several attendees dancing into the small hours . We acknowledged Novartis for their grant to support our member’s attendance at he ASM .

The meeting closed with presentation of the awards, generously supported by Astellas . Congratulations to: Reuben Broom Best of the Best Oral; Weranja Ranasinghe Best of the Best Poster; Rod McDowell Best of the Best Nursing/Allied Health; and Mum Sem Liew Best of the Best Trainee/Fellow

• Bavanthi Balakrishnar • Renu Eapen • Marion Fournier • Peter Fox • Jeremy Grummet • Mun Sem Liew • Rob McDowall • Visalini Nair-Shalliker • David Pook • Weranja Ranasinghe • Siva Shankar • Ben Tran • Trina Yeadon

Acknowledgements

We acknowledge the valuable support we receive from Cancer Australia .

To our sponsors, it is only through your level of commitment that we can consider hosting such a high quality meeting over the 3 days . We acknowledge and thank our 2012 major meeting sponsors: • Platinum Sponsor – Janssen Cilag; • Gold Sponsors - Pfizer Oncology and Sanofi; • Silver Sponsors – Ipsen; Amgen Oncology; Novartis Oncology; and the Prostate

Cancer Foundation of Australia; and • Bronze Sponsors - AstraZeneca and Cancer Institute NSW .

Our international faculty was superb and we are grateful to the following companies / organisations for their additional support to cover the costs of their attendance: Dr Donna Berry – CNSA and ANZUP; Prof Michel Bolla’s attendance – Ipsen; Dr Daniel Heng – Pfizer Oncology; Dr Sharokh Shariat – ANZUP;

We are also grateful to • Bayer for sponsoring the Barista and

Café Bar and • Astellas for the Best of the Best Oral and Poster Awards .

My heartfelt thanks to my co-convenors Amy Hayden, Paul Sved and Shomik Sengupta for their outstanding work and support .

The ANZUP ASM highlighted the wonderful depth and breadth of research and collaboration across genitourinary cancers with the buzz and verbal feedback very positive . The ANZUP ASM will continue to grow and become not only the major GU clinical trials research meeting but also a key meeting for our members and stakeholders for networking and developing new research collaborations . Make sure you have diarised the 2013 ASM on the Gold Coast 14-16 July and if you are not a member you should do so - its free and you can join online at www.anzup.org.au

Platinum Sponsor

Gold Sponsors

Silver Sponsors

Bronze Sponsors